First human trial of NAMI-A
In a phase I study in 24 patients with solid tumours, the ruthenium compound NAMI-A, which had shown antimetastatic activity in preclinical studies, caused painful blisters at high doses; 300 mg/m2/day was advised for further testing.
Built / tested: NAMI-A
As reported in: Rademaker-Lakhai, van den Bongard, Pluim et al. (2004). A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent. Clinical Cancer Research. doi:10.1158/1078-0432.ccr-03-0746